Healthcare Industry News: HSMN NewsFeed

Devices Gastroenterology

 News Release - October 24, 2017

Stretta Therapy 15-Year Data Shows Long-Term Efficacy of Non-Surgical GERD Treatment

New Study Presented During ACG2017

NORWALK, Conn., Oct. 24, 2017 -- (Healthcare Sales & Marketing Network) -- Mederi Therapeutics Inc. has announced new data on Stretta Therapy presented at the 2017 American College of Gastroenterology Congress (ACG2017). Authored by Dr. Alvaro Reymunde from the Advanced Endoscopy Center in Ponce, Puerto Rico, the study documented long-term effectiveness of this non-surgical, endoscopic procedure for Gastroesophageal Reflux Disease (GERD)

GERD is a chronic problem and proton pump inhibitors (PPIs) don't control symptoms in about one-third of patients. Stretta is an option between medications and surgery that is performed in an endoscopic, outpatient procedure.

The study reported on 35 patients who received Stretta and were followed for 15 years to access long-term efficacy. Statistically significant results included:
  • No evidence of Barretts or esophageal neoplasia on endoscopy at follow-up
  • 100% were on daily PPI at baseline – at follow-up, no patients were taking PPI daily
  • 20/35 patients underwent pH testing and had DeMeester scores of 4.5
  • Sustained improvement in Quality of Life (QOL) scores
  • Sustained improvement in GERD symptoms scores
The study concluded that Stretta is a safe and effective treatment with results lasting over 15 years, especially in patients who had at least a partial response to PPI's. Dr. Reymunde explained, "Stretta has been a highly dependable option, and has helped our patients get relief from their chronic GERD, eliminate or reduce their medications, and avoid surgery. We have seen all of these patients at least annually, allowing us to confirm the durability, effectiveness, and safety of Stretta."

Earlier this year a large meta-analysis including 28 studies and 2,468 patients also concluded that Stretta is safe, effective and durable. Statistically significant improvements were seen in Quality of Life, GERD Symptoms, PPI Use, Esophageal Acid exposure, and reduced incidence of Erosive Esophagitis. Findings also showed Stretta exhibited less than a 1% complication rate.

Bob Knarr, CEO of Mederi added, "This exceptionally long-term follow-up at 15 years mirrors the findings of the previously published 10 and 8 year studies. The durability of effect, when paired with health economic data published in 2016, shows significant cost savings when using Stretta as compared to using PPIs or Surgery to treat GERD. Patients have fewer symptoms – take less medications – and visit their doctor less after a Stretta procedure compared to medications or surgery."

MEDERI® AND STRETTA®

Mederi manufactures innovative medical devices that use non-ablative radiofrequency (RF) energy to treat digestive diseases. Mederi's Stretta Therapy applies low levels of RF energy to thicken the muscle between the stomach and esophagus, decreasing compliance and improving GERD symptoms. Stretta has been proven safe and effective for GERD in more than 40 studies and is available worldwide.

For more information visit www.stretta-therapy.com.


Source: Mederi Therapeutics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.